iPrime is an emerging leader in next-generation IVDs for pathogen detection. We additionally focus on a world-class capability for single-protein interactions, leading to a new generation of immunotherapies and diagnostic agents. Our core mission is to provide these innovative solutions to some of the most pressing issues in healthcare delivery today.

iPrime applies propriety platforms to the field of single-molecule detection, based on its “Direct Detect” platform. This affords near “real-time” analysis of pathogens, contaminants and a range of misfolded protein structures, driving new capability in healthcare, industrial and commercial applications.

iPrime was founded by Gryphon Capital, which has over 30 years of success in Biotechnology, Advanced Diagnostics and Medtech. Based in Sydney, Australia, iPrime has a series of collaborations with a range of research facilities and universities globally. iPrime is highly committed to ESG principles, with the wider impacts of all our actions taken into consideration with a view to benefiting society as a whole.